THOUSAND
OAKS, Calif., May 2, 2022
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today released its 2021
Environmental, Social & Governance (ESG) report, providing a
comprehensive overview of the many ways the Company is doing its
part to build a better, healthier world.
To view the Multimedia News Release, please visit:
https://www.multivu.com/players/English/8812857-amgen-releases-annual-environmental-social-governance-report/
"Our core business of improving human health, in and of itself,
contributes meaningfully to the greater good," said
Judy Brown, senior vice president,
Corporate Affairs at Amgen, "and through our ESG programs, we are
building on that foundation to address other challenging issues
facing our society."
Amgen's latest ESG report tracks the Company's progress across
four categories:
- Healthy People: We focus on removing barriers that
limit equitable access to healthcare so that people can live their
healthiest lives. In 2021, for example, the Amgen Safety Net
Foundation1 provided $2.2
billion2 of the Company's medicines, at no cost,
to uninsured or underinsured patients in the U.S.
- Healthy Society: We work toward a more just society
for our employees and the people we serve. In 2021, no-cost
science education programs funded by the Amgen
Foundation1 reached more than 27 million students and
educators globally, inspiring the next generation of innovators and
helping to level the playing field for those who traditionally have
lacked access to world-class science education.
- Healthy Planet: We prioritize sustainability and
aim to minimize our environmental impact to preserve
natural resources for generations to come. Amgen made
continued progress last year toward its goal of achieving carbon
neutrality in our operations by 20273.
- A Healthy Amgen: We hold ourselves to high standards in
our operations – working to ensure our actions and culture reflect
Amgen values. In 2021, Amgen added an ESG goal to the
Company's goals for our annual incentive plans to focus our entire
Company on activities supporting achievement of our 2027
environmental sustainability targets and to strengthen and improve
the Company's diversity, inclusion, and belonging efforts. To
further our progress, Amgen has included an ESG goal again for
2022.
Amgen's ESG progress is reflected in the wide range of
recognitions the Company has earned. In just the past six
months, Amgen has been named to Newsweek magazine's list of
"America's Most Responsible Companies" for the third consecutive
year; JUST Capital's list of "America's Most JUST Companies" for
the fifth consecutive year; Barron's list of "America's Most
Sustainable Companies" for the second consecutive year; and the
Human Rights Campaign Foundation's list of "Best Places to Work for
LGBTQ+ Equality" for the sixth consecutive year.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing, and delivering
innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease
and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones
Industrial Average and is also part of the Nasdaq-100 index.
In 2021, Amgen was named one of the 25 World's Best Workplaces™ by
Fortune and Great Place to Work™ and one of the 100 most
sustainable companies in the world by Barron's.
Forward-Looking Statements
This news release contains
forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the
outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd.,
Kyowa-Kirin Co., Ltd., or any collaboration to manufacture
therapeutic antibodies against COVID-19), the performance of
Otezla® (apremilast) (including anticipated Otezla sales growth and
the timing of non-GAAP EPS accretion), the Five Prime Therapeutics,
Inc. acquisition, or the Teneobio, Inc. acquisition, as well as
estimates of revenues, operating margins, capital expenditures,
cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer
and prescriber patterns or practices, reimbursement activities and
outcomes, effects of pandemics or other widespread health problems
such as the ongoing COVID-19 pandemic on our business, and other
such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed
below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent annual
report on Form 10-K and any subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen
is providing this information as of the date of this news release
and does not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. An outbreak
of disease or similar public health threat, such as COVID-19, and
the public and governmental effort to mitigate against the spread
of such disease, could have a significant adverse effect on the
supply of materials for our manufacturing activities, the
distribution of our products, the commercialization of our product
candidates, and our clinical trial operations, and any such events
may have a material adverse effect on our product development,
product sales, business and results of operations. We rely on
collaborations with third parties for the development of some of
our product candidates and for the commercialization and sales of
some of our commercial products. In addition, we compete with other
companies with respect to many of our marketed products as well as
for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to collaborate with or acquire other companies, products or
technology, and to integrate the operations of companies or to
support the products or technology we have acquired, may not be
successful. A breakdown, cyberattack or information security breach
could compromise the confidentiality, integrity and availability of
our systems and our data. Our stock price is volatile and may be
affected by a number of events. Our business and operations may be
negatively affected by the failure, or perceived failure, of
achieving our environmental, social and governance objectives. The
effects of global climate change and related natural disasters
could negatively affect our business and operations. Global
economic conditions may magnify certain risks that affect our
business. Our business performance could affect or limit the
ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase our common stock. We may
not be able to access the capital and credit markets on terms that
are favorable to us, or at all.
CONTACT: Amgen, Thousand
Oaks
Jessica Akopyan, 805-440-5721
(media)
Michael Strapazon, 805-313-5553
(media)
Annie Kasparian, 805-447-1060
(investors)
1 Amgen Safety Net Foundation and The Amgen
Foundation, Inc. are separate legal entities entirely funded by
Amgen.
2 Valued at Wholesale Acquisition Cost.
3 Carbon neutrality goal refers to Scope 1 and 2
emissions.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
View original
content:https://www.prnewswire.com/news-releases/amgen-releases-annual-environmental-social--governance-report-301536594.html
SOURCE Amgen